TRCT
PHIO icon

Tower Research Capital (TRC)’s Phio Pharmaceuticals PHIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.36K Sell
6,206
-1,414
-19% -$1.61K ﹤0.01% 4219
2026
Q1 		$9.3K Buy
+7,620
New +$8.69K ﹤0.01% 3933
2025
Q4 		– Sell
-406
Closed -$1.01K – 5479
2025
Q3 		$1.01K Buy
+406
New +$924 ﹤0.01% 4894
2025
Q2 		– Sell
-2,501
Closed -$3.25K – 5503
2025
Q1 		$3.25K Sell
2,501
-2,181
-47% -$4.03K ﹤0.01% 4445
2024
Q4 		$8.43K Buy
4,682
+3,508
+299% +$9.53K ﹤0.01% 3995
2024
Q3 		$4.05K Buy
1,174
+537
+84% +$1.93K ﹤0.01% 4700
2024
Q2 		$3.97K Buy
637
+4
+0.6% +$26 ﹤0.01% 4838
2024
Q1 		$3.87K Sell
633
-2
-0.3% -$14 ﹤0.01% 4777
2023
Q4 		$4.34K Buy
635
+412
+185% +$4.23K ﹤0.01% 4965
2023
Q3 		$3.03K Buy
223
+76
+52% +$1.58K ﹤0.01% 5064
2023
Q2 		$3.8K Buy
+147
New +$5.16K ﹤0.01% 5022
2023
Q1 		– Sell
-48
Closed -$2K – 6177
2022
Q4 		$2K Sell
48
-3
-6% -$154 ﹤0.01% 5406
2022
Q3 		$3K Sell
51
-25
-33% -$1.89K ﹤0.01% 5412
2022
Q2 		$6K Buy
+76
New +$7.14K ﹤0.01% 4941
2021
Q3 		– Sell
-6
Closed -$2K – 6064
2021
Q2 		$2K Buy
+6
New +$1.48K ﹤0.01% 5064
2020
Q4 		– Sell
-5
Closed -$1K – 5348
2020
Q3 		$1K Buy
+5
New +$1.27K ﹤0.01% 4722
2018
Q4 		– Hold
0
– – – 4229
2018
Q3 		– Hold
0
– – – 4141
2016
Q4 		– Hold
0
– -$1K – 4262
2016
Q3 		– Hold
0
– – – 3343
2016
Q1 		– Hold
0
– – – 4726
2015
Q4 		– Hold
0
– – – 4918
2015
Q1 		– Hold
0
– -$5K – 4805
2014
Q4 		– Hold
0
– – – 2735
2014
Q3 		– Hold
0
– -$5K – 4782
2014
Q2 		– Hold
0
– – – 2867
2014
Q1 		– Hold
0
– – – 2010

Other funds holding PHIO

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Tower Research Capital (TRC)'s PHIO Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Phio Pharmaceuticals (PHIO) stake by 19% in Q2 2026, selling an estimated $1.61K and leaving 6,206 shares worth $6.36K. The position accounts for ﹤0.01% of the portfolio, ranked #4219.

Tower Research Capital (TRC) first reported a position in PHIO in Q3 2020 and has held it in 16 quarters since. The position peaked at $9.3K in Q1 2026. 24 funds tracked by Wall St. Rank hold PHIO as of Q2 2026.

  • Tower Research Capital (TRC) held 6,206 shares of Phio Pharmaceuticals worth $6.36K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,414 Phio Pharmaceuticals shares in Q2 2026, an estimated $1.61K.
  • Phio Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4219 holding.
  • Tower Research Capital (TRC) first reported a position in Phio Pharmaceuticals in Q3 2020 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s Phio Pharmaceuticals position peaked at $9.3K in Q1 2026.
  • 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.